SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY ARTICLE M impact

Novo Nordisk Shares Rise 3% on Weight-Loss Data, Hemophilia Approval

Novo Nordisk shares rose 3% to 286.70 Danish kroner after the company released encouraging weight-loss drug study results and European regulators approved a hemophilia treatment.

NOVOB

By Joe StonorNovo Nordisk shares rose after the Danish drugmaker released encouraging results from studies into the efficacy of its weight-loss drugs and European regulators approved a hemophilia treatment.Copenhagen-listed shares rose 3% to 286.70 Danish kroner in early afternoon European trade, p…

Related stories